1585 related articles for article (PubMed ID: 23995860)
1. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.
Yepuru M; Wu Z; Kulkarni A; Yin F; Barrett CM; Kim J; Steiner MS; Miller DD; Dalton JT; Narayanan R
Clin Cancer Res; 2013 Oct; 19(20):5613-25. PubMed ID: 23995860
[TBL] [Abstract][Full Text] [Related]
2. The Steroidogenic Enzyme AKR1C3 Regulates Stability of the Ubiquitin Ligase Siah2 in Prostate Cancer Cells.
Fan L; Peng G; Hussain A; Fazli L; Guns E; Gleave M; Qi J
J Biol Chem; 2015 Aug; 290(34):20865-20879. PubMed ID: 26160177
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5α-reductase inhibitor finasteride.
Byrns MC; Mindnich R; Duan L; Penning TM
J Steroid Biochem Mol Biol; 2012 May; 130(1-2):7-15. PubMed ID: 22265960
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer.
Liu C; Armstrong CM; Lou W; Lombard A; Evans CP; Gao AC
Mol Cancer Ther; 2017 Jan; 16(1):35-44. PubMed ID: 27794047
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of AKR1C3 exposes a potential epigenetic susceptibility in prostate cancer cells.
Doig CL; Battaglia S; Khanim FL; Bunce CM; Campbell MJ
J Steroid Biochem Mol Biol; 2016 Jan; 155(Pt A):47-55. PubMed ID: 26429394
[TBL] [Abstract][Full Text] [Related]
6. Abiraterone inhibits 3β-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer.
Li R; Evaul K; Sharma KK; Chang KH; Yoshimoto J; Liu J; Auchus RJ; Sharifi N
Clin Cancer Res; 2012 Jul; 18(13):3571-9. PubMed ID: 22753664
[TBL] [Abstract][Full Text] [Related]
7. Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma.
Fung KM; Samara EN; Wong C; Metwalli A; Krlin R; Bane B; Liu CZ; Yang JT; Pitha JV; Culkin DJ; Kropp BP; Penning TM; Lin HK
Endocr Relat Cancer; 2006 Mar; 13(1):169-80. PubMed ID: 16601286
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 2-methyl-1-{1-[(5-methyl-1H-indol-2-yl)carbonyl]piperidin-4-yl}propan-2-ol: a novel, potent and selective type 5 17β-hydroxysteroid dehydrogenase inhibitor.
Watanabe K; Kakefuda A; Yasuda M; Enjo K; Kikuchi A; Furutani T; Naritomi Y; Otsuka Y; Okada M; Ohta M
Bioorg Med Chem; 2013 Sep; 21(17):5261-70. PubMed ID: 23845281
[TBL] [Abstract][Full Text] [Related]
9. ERG/AKR1C3/AR Constitutes a Feed-Forward Loop for AR Signaling in Prostate Cancer Cells.
Powell K; Semaan L; Conley-LaComb MK; Asangani I; Wu YM; Ginsburg KB; Williams J; Squire JA; Maddipati KR; Cher ML; Chinni SR
Clin Cancer Res; 2015 Jun; 21(11):2569-79. PubMed ID: 25754347
[TBL] [Abstract][Full Text] [Related]
10. Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors.
Mitsiades N; Sung CC; Schultz N; Danila DC; He B; Eedunuri VK; Fleisher M; Sander C; Sawyers CL; Scher HI
Cancer Res; 2012 Dec; 72(23):6142-52. PubMed ID: 22971343
[TBL] [Abstract][Full Text] [Related]
11. Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer.
Hofland J; van Weerden WM; Dits NF; Steenbergen J; van Leenders GJ; Jenster G; Schröder FH; de Jong FH
Cancer Res; 2010 Feb; 70(3):1256-64. PubMed ID: 20086173
[TBL] [Abstract][Full Text] [Related]
12. Activin A stimulates AKR1C3 expression and growth in human prostate cancer.
Hofland J; van Weerden WM; Steenbergen J; Dits NF; Jenster G; de Jong FH
Endocrinology; 2012 Dec; 153(12):5726-34. PubMed ID: 23024260
[TBL] [Abstract][Full Text] [Related]
13. Testosterone boosts for treatment of castration resistant prostate cancer: an experimental implementation of intermittent androgen deprivation.
Thelen P; Heinrich E; Bremmer F; Trojan L; Strauss A
Prostate; 2013 Nov; 73(15):1699-709. PubMed ID: 23868789
[TBL] [Abstract][Full Text] [Related]
14. Development of potent and selective indomethacin analogues for the inhibition of AKR1C3 (Type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase) in castrate-resistant prostate cancer.
Liedtke AJ; Adeniji AO; Chen M; Byrns MC; Jin Y; Christianson DW; Marnett LJ; Penning TM
J Med Chem; 2013 Mar; 56(6):2429-46. PubMed ID: 23432095
[TBL] [Abstract][Full Text] [Related]
15. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.
Stanbrough M; Bubley GJ; Ross K; Golub TR; Rubin MA; Penning TM; Febbo PG; Balk SP
Cancer Res; 2006 Mar; 66(5):2815-25. PubMed ID: 16510604
[TBL] [Abstract][Full Text] [Related]
16. HOXC8 inhibits androgen receptor signaling in human prostate cancer cells by inhibiting SRC-3 recruitment to direct androgen target genes.
Axlund SD; Lambert JR; Nordeen SK
Mol Cancer Res; 2010 Dec; 8(12):1643-55. PubMed ID: 21047772
[TBL] [Abstract][Full Text] [Related]
17. AKR1C3 Inhibitor KV-37 Exhibits Antineoplastic Effects and Potentiates Enzalutamide in Combination Therapy in Prostate Adenocarcinoma Cells.
Verma K; Gupta N; Zang T; Wangtrakluldee P; Srivastava SK; Penning TM; Trippier PC
Mol Cancer Ther; 2018 Sep; 17(9):1833-1845. PubMed ID: 29891491
[TBL] [Abstract][Full Text] [Related]
18. Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer.
Wako K; Kawasaki T; Yamana K; Suzuki K; Jiang S; Umezu H; Nishiyama T; Takahashi K; Hamakubo T; Kodama T; Naito M
J Clin Pathol; 2008 Apr; 61(4):448-54. PubMed ID: 17720776
[TBL] [Abstract][Full Text] [Related]
19. Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer.
Liu C; Lou W; Zhu Y; Yang JC; Nadiminty N; Gaikwad NW; Evans CP; Gao AC
Cancer Res; 2015 Apr; 75(7):1413-22. PubMed ID: 25649766
[TBL] [Abstract][Full Text] [Related]
20. AKR1C3 as a target in castrate resistant prostate cancer.
Adeniji AO; Chen M; Penning TM
J Steroid Biochem Mol Biol; 2013 Sep; 137():136-49. PubMed ID: 23748150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
